Novavax's (NVAX) COVID-19 Booster Recommended in Switzerland
Inc. Novavax The use of NVAX's protein-based COVID-19 vaccination has been advised by the Federal Office of Public Health (FOPH) of Switzerland, the company reported.
Adults in Switzerland who are 18 years of age and older can get heterologous and homologous booster doses of nuvaxovid (NVX-CoV2373).
Whether or not the original vaccination regimen series was finished with Nuvaxovid, Nuvaxovid can now be given as a booster dose to adults.
Novavax will be permitted to target a bigger portion of Switzerland's adult population thanks to FOPH's decision.
Who have not yet received a booster dose after finishing a main immunisation series with a vaccine produced by a different firm.
Earlier this year, Swissmedic had temporarily approved Nuvaxovid for use in persons 18 years of age or older.
The Nuvaxovid vaccine has previously received approval for use in New Zealand, Australia, Japan, Israel, and the European Union as a booster dosage.
The Korean Centers for Disease Control and Prevention suggested last month that people can take Nuvaxovid off-label as a booster dosage.